the aid library

LIST OPTIONS

Filter

6064

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (613)

View PDF (811)

Interim National Guidelines for Monkeypox Outbreak Response

Federal Ministry of Health - Nigeria Centre for Disease Contro (2017) C2

This document provides information and recommendations for action, based on the current available knowledge around monkeypox. It is a first draft which will be updated in light of evolving evidence and additional information as they become available.

Download (18439)

View PDF (2991)

Paediatrics for Doctors in Papua New Guinea

Frank Shann and John Vince (2003)

A guide for doctors providing health services for children. 2nd edition

Download (1387)

View PDF (2362)

Guidelines for the Treatment of Chronic Hepatitis B and C Viral Infections in Kenya
recommended

Prof. G. N. Lule, Dr. B. Nyawira Gastroenterology Society of Kenya , Republic of Keny (2015) C1

Download (465)

View PDF (660)

Toolkit on disability for AFRICA: CULTURE, BELIEFS, AND DISABILITY

United Nations Division for Social Policy Development (DSPD) & United Nations Department of Economic and Social Affairs (DESA) (2016) C1

Module 13

Download (310)

View PDF (324)

South African Health Review 2019
recommended

Sanders, S. Health System Trust HST (2020) C1

22nd edition The purpose of the SAHR has always been to analyse and assess progress and challenges in key areas of the health system, and to propose recommendations for improvement. We are pleased to continue this tradition in the 2019 edition, which presents a unique collection of perspectives on ... more

Download (488)

View PDF (793)

The Core Elements of Human Antibiotic Stewardship Programs in Resource-Limited Settings: National and Hospital Levels
recommended

Centers for Disease Control and Prevention CDC (2018) C_CDC

Formularies are lists of antibiotics that are suggested for certain healthcare settings. In developing a recommended formulary, countries should consider the needs of patients and facilities where they receive care. For example, clinicians in rural or primary health centers may need wide access to f... more

Download (393)

View PDF (388)

Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance

World Health Organization WHO (2021) C_WHO

An Action Framework and annexe to Immunization Agenda 2030 (Draft version) 27 January 2021

Download (300)

View PDF (390)

Key aspects of the global response to the COVID-19 crisis: an inventory one year after the official announcement of the pandemic

Rüppel, T. (2021) CC

Download (283)

View PDF (352)

Global competency and outcomes framework for universal health coverage

World Health Organization WHO (2022) C_WHO

Download (282)

View PDF (283)

WHO Drug Information - Volume 36, No. 4

World Health Organisation (WHO) (2023) C_WHO

Pharmaceutical News Evaluation of Saccharide Content of the WHO 2nd International Standard for Haemophilus Influenzae Polysaccharide Polyribosyl Ribitol Phosphate (PRP) by HPAECPAD Analysis Following Acid Hydrolysis Consultation Documents Lamivudine and tenofovir disoproxil fumarate tablets (lami... more

Download (920)

View PDF (1407)

Humanitarian Standards Pocket Guide

The Sphere Project; World Vision Singapore (2006)

Download (2446)

View PDF (2936)

Treatment of Mycobacterium Ulcerans Disease (Buruli Ulcer)
recommended

World Health Organization WHO WHO (2012) C_WHO

Guidance for health workers

Download (384)

View PDF (402)

WHO recommendations on outpatient settings for induction of labour

World Health Organization WHO (2022) C_WHO

The primary audience for these recommendations includes health professionals who are responsible for developing national and local health-care guidelines and protocols and health workers involved in the provision of care to women and their newborns during pregnancy, labour and childbirth; this inclu... more